Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children

Simple item page
dc.catalogadorpau
dc.contributor.authorAbarca, K.
dc.contributor.authorIbánez, I.
dc.contributor.authorPerret Pérez, Cecilia
dc.contributor.authorVial, P.
dc.contributor.authorZinsou, J. A.
dc.date.accessioned2024-03-08T19:00:11Z
dc.date.available2024-03-08T19:00:11Z
dc.date.issued2008
dc.description.abstractObjectives: To compare the immunogenicity, safety, and interchangeability of two pediatric hepatitis A vaccines, Avaxim 80U-Pediatric® and Havrix 720®, in Chilean children. Methods: In this randomized trial, 332 hepatitis A virus (HAV) seronegative children from 1 to 15 years of age received two doses of Avaxim, two doses of Havrix, or Havrix followed by Avaxim, 6 months apart. Anti-HAV antibody titers were measured before and 14 days after the first dose of vaccine, and before and 28 days after the second dose of vaccine. Immediate reactions were monitored; reactogenicity was evaluated from parental reports. Results: Seroconversion rates after the first vaccination were 99.4% and 100% for Avaxim and Havrix, respectively. Anti-HAV geometric mean concentrations (GMCs) were 138 mIU/ml for Havrix (95% confidence interval (CI): 120; 159) and 311 mIU/ml for Avaxim (95% CI: 274; 353). GMCs increased to 4008 mIU/ml after two doses of Havrix, 8537 mIU/ml following two doses of Avaxim, and 7144 mIU/ml in children who received Havrix with Avaxim as the second dose. Following the first injection, 36% of subjects given Avaxim and 44% given Havrix reported local reactions; 38% of subjects in the Avaxim group and 40% in the Havrix group reported systemic reactions related to vaccination. Solicited reactions were less frequent after the second dose of Avaxim or Havrix, occurring in 27% to 37% of subjects. Conclusions: No significant difference in seroconversion rates was seen 14 days after a single dose of vaccine. A two-dose schedule with either vaccine or with Havrix/Avaxim provided a strong booster response. Both vaccines were well tolerated and can be recommended for routine vaccination of Chilean children. Avaxim 80 may be used to complete a vaccine schedule begun with Havrix 720. © 2007 International Society for Infectious Diseases.
dc.format.extent7 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1016/j.ijid.2007.08.006
dc.identifier.urihttps://doi.org/10.1016/j.ijid.2007.08.006
dc.identifier.urihttp://www.scopus.com/inward/record.url?eid=2-s2.0-42149105259&partnerID=MN8TOARS
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/84312
dc.identifier.wosidWOS:000255834000009
dc.information.autorucEscuela de Medicina; Perret Pérez, Cecilia; 0000-0002-1535-1204; 80387
dc.issue.numero13
dc.language.isoen
dc.nota.accesoContenido completo
dc.revistaInternational Journal of Infectious Diseases
dc.rightsacceso abierto
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleImmunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children
dc.typeartículo
dc.volumen12
sipa.codpersvinculados80387
sipa.trazabilidadORCID;2024-01-15
Files
Collections
Artículos de revistas